Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00386750
Status:
TERMINATED
Last Update Posted:
2012-04-27
First Post:
2006-10-11
Brief Title:
Safety of Artemether - Lumefantrine and Other Malaria Drugs and Their Effect on the Auditory Function
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Single-center Study of the Effects of Co-artemether Atovaquone-proguanil and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
THIS STUDY IS NOT ENROLLING PATIENTS IN THE USA
To evaluate the effects of artemether lumefantrine on the auditory function
To evaluate the effects of artemether lumefantrine on the auditory function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None